ХС243 / Pharmenterprises - LARVOL DELTA

Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers. (clinicaltrials.gov) - P1 | N=38 | Completed | Sponsor: PHARMENTERPRISES LLC | Recruiting ➔ Completed | Trial completion date: May 2023 ➔ Sep 2023 | Trial primary completion date: May 2023 ➔ Sep 2023

Trial completion • Trial completion date • Trial primary completion date

Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers. (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: PHARMENTERPRISES LLC

New P1 trial